Clozapine-induced agranulocytosis
DOI:
https://doi.org/10.24265/horizmed.2020.v20n1.10Keywords:
Clozapine, Antipsychotic agents, Agranulocytosis, Neutropenia, PharmacovigilanceAbstract
Clozapine currently remains the gold standard for treatment-resistant schizophrenia, but only under an adequate hematological monitoring, because it is associated with agranulocytosis. Clozapine is metabolized to produce pharmacologically active N-desmethylclozapine, inactive clozapine N-oxide and reactive oxygen species (nitrenium ion). A neutrophil count < 1000 cells/mm3 corresponds to a state of neutropenia. Agranulocytosis is a severe state of neutropenia with an absolute neutrophil count < 500 cells/mm3. Clozapine is associated with agranulocytosis in approximately 0.8 % of the patients, with an increased risk in older people and women. There are two mechanisms that explain the clozapine-induced agranulocytosis: immunological (response mediated by the immune system against haptenized neutrophils) and toxic (by the action of the metabolites N-desmethylclozapine and nitrenium ion). Pharmacogenetics represents a valuable tool to achieve the so-called personalized medicine by adapting and individualizing the treatment based on the genetic markers of each patient. Several studies have shown a potential association of clozapine-induced agranulocytosis with certain HLA haplotypes (HLA-B38, DR4, DQw3 and DQB1). After a patient has presented agranulocytosis, three mechanisms of clozapine rechallenge are known: simple, with lithium and with factors that stimulate granulocyte colonies. Due to the risk of agranulocytosis, clozapine formulations are available only through a controlled distribution, with a detailed record of the patients, and with a mandatory and systematized pharmacovigilance.
Downloads
References
Stepnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018; 23(8).
Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/ granulocytopenia: mechanisms and monitoring. Curr Opin Hematol. 2018; 25(1): 22-8.
Pirmohamed M, Park K. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 1997; 7(2): 139-58.
De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018; 9(5): 237-56.
Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health. 2017; 20(1): 1-9.
Mukku SSR, Sivakumar PT, Varghese M. Clozapine use in geriatric patients- Challenges. Asian J Psychiatry. 2018; 33: 63-7.
Bishara D, Taylor D. Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging. 2014; 31(1): 11-20.
Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007; 21(11): 911-36.
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329(3): 162-7.
Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry. 2006; 188: 255-63.
Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007; 21(1): 25-35.
Zhang J-P, Malhotra AK. Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol. 2013; 9(2): 183-91.
Combs MD, Perry PJ, Bever KA. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy. 1997; 17(6): 1300-4.
Wiciński M, Węclewicz MM, Miętkiewicz M, Malinowski B, Grześk E, Klonowska J. Potential mechanisms of hematological adverse drug reactions in patients receiving clozapine in combination with proton pump inhibitors. J Psychiatr Pract. 2017; 23(2): 114-20.
Regen F, Herzog I, Hahn E, Ruehl C, Le Bret N, Dettling M, et al. Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol. 2017; 316: 10-6.
Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Metaanalysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018; 138(2): 101-9.
Inada K, Oshibuchi H, Ishigooka J, Nishimura K. Analysis of clozapine use and safety by using comprehensive national data from the japanese clozapine patient monitoring service. J Clin Psychopharmacol. 2018; 38(4): 302-6.
Steinauer LM, Leung JG, Burkey BW, McGrane IR, Letts V, Goren JL, et al. A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization. J Child Adolesc Psychopharmacol. 2018; 28(9): 615-9.
Tunsirimas N, Pariwatcharakul P, Choovanichvong S, Ratta-Apha W. Clozapine-induced agranulocytosis and leukopenia: incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian J Psychiatry. 2019; 41: 13-6.
Law A, Croucher M. Prescribing trends and safety of clozapine in an older persons mental health population. Int Psychogeriatr. 2019; 1-7.
Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology (Berl). 2018; 235(7): 1915-21.
Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2019; 1-12.
Numata S, Umehara H, Ohmori T, Hashimoto R. Clozapine pharmacogenetic studies in schizophrenia: efficacy and agranulocytosis. Front Pharmacol. 2018; 9: 1049.
De With SAJ, Pulit SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J. 2017; 17(4): 304-11.
Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 acses. Am J Ther. 2018; 25(2): e218-23.
Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. J Clin Psychiatry. 2013; 74(6): 603-13.
Simon L, Cazard F. Clozapine rechallenge after neutropenia in resistant schizophrenia: a review. Encephale. 2016; 42(4): 346-53.
Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012; 134(2-3): 180-6.
Myles N, Myles H, Clark SR, Bird R, Siskind D. Use of granulocytecolony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: a systematic review of the literature and clinical recommendations. Aust N Z J Psychiatry. 2017; 51(10): 980-9.
Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. The use of granulocyte colony-stimulating factor in clozapine rechallenge: a systematic review. J Clin Psychopharmacol. 2017; 37(5): 600-4.
Winckel K, Siskind D. Clozapine in primary care. Aust Prescr. 2017; 40(6): 231-6.
Citrome L, McEvoy JP, Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses. 2016; 10(3): 163-77.
Inada K, Ishigooka J, Niho R. Clozapine. Jpn J Clin Med. 2013; 71(4): 678-83.
De Fazio P, Gaetano R, Caroleo M, Cerminara G, Maida F, Bruno A, et al. Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat. 2015; 11: 1995-2003.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
